In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 121 to 130 of 301

TitleTypeExpected publication date
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]Technology appraisal guidance
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194]Technology appraisal guidanceTBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]Technology appraisal guidanceTBC
Iptacopan for treating primary IgA nephropathy [ID6640]Technology appraisal guidanceTBC
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]Technology appraisal guidanceTBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Technology appraisal guidanceTBC
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]Technology appraisal guidanceTBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]Technology appraisal guidanceTBC
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]Technology appraisal guidance
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All